drugset
drugset / Trial / NCT05245084

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg

NCT05245084 ↗

Phase 1 Completed 64 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386(3)

Timeline

Start
2022-03-15
Primary completion
2022-06-06
Completion
2022-06-20

Drugs

EvaluationDrugModalityDoseRoute
Subject CKD-386(3) Unknown — Oral
Subject D013 Unknown — Oral
Subject D326 Unknown — Oral
Subject D337 Unknown — Oral

Indications

hyperlipidemia, combined, 2